• Pickering Multiple Emulsions for mRNA Cancer Vaccines

  2026-08-26

  Yufei Xia’s 2024 dissertation develops water-in-oil-in-water Pickering multiple emulsions for protein and mRNA cancer vaccines, with calcium phosphate emerging as the most effective particle stabilizer in the reported experiments. The work connects cargo retention, dendritic-cell targeting, cytoplasmic release, and tumor control, while also identifying why particle charge and biodistribution must be optimized together.

• KPT-330 (Selinexor): CRM1 Inhibitor Guide

  2026-08-25

  KPT-330, also called Selinexor, is an orally bioavailable selective CRM1/XPO1 inhibitor used to study nuclear export, cancer-cell signaling, apoptosis, and osteoclastogenesis. Peer-reviewed 2026 evidence shows that KPT-330 suppresses RANKL-induced osteoclastogenesis and protects joint structure in a mouse osteoarthritis model, while product information documents activity in oncology research models.

• O-propargyl-puromycin (OPP) for Protein Synthesis

  2026-08-25

  O-propargyl-puromycin (OPP) provides a rapid, pulse-based readout of nascent protein production in cells, with applications ranging from B-cell immunology to proteomics. This guide explains how to connect OPP labeling with mitochondrial and functional assays, optimize click chemistry, and distinguish genuine translation changes from technical artifacts.

• CX-5461 RNA Polymerase I Inhibitor Workflow

  2026-08-24

  CX-5461 gives cancer researchers a focused way to connect Pol I-driven rRNA suppression with DNA damage, mitotic catastrophe, autophagy, and senescence. This workflow translates cervical cancer findings into practical concentration-response, mechanism, and cisplatin-sensitization assays while highlighting formulation and interpretation safeguards.

• Lipo3K Transfection Reagent for APOL1 Studies

  2026-08-23

  Build cleaner APOL1 variant, splice-isoform, and APOL3 interaction experiments with a low-toxicity lipid transfection reagent. Lipo3K supports plasmid delivery, siRNA workflows, and DNA–siRNA co-transfection across adherent, suspension, and challenging cell models.

• CAFs, Lactylation, and Oxaliplatin Resistance in CRC

  2026-08-22

  The reference study identifies a CAF-derived lactate–ANTXR1 axis that links tumor metabolism, protein lactylation, cancer stemness, and oxaliplatin resistance in colorectal cancer. Its combination of mechanistic molecular analysis with genetic, pharmacological, and xenograft experiments supports disruption of tumor–stromal lactate transfer as a potential strategy for improving chemotherapy response.

• Dasatinib (BMS-354825): Cancer Research Workflows

  2026-08-21

  Dasatinib (BMS-354825) offers a practical way to interrogate Src and Bcr-Abl signaling across leukemia, epithelial-mesenchymal transition, and metastatic cancer models. This workflow-centered guide covers solvent handling, target-engagement assays, translational model selection, and troubleshooting for reproducible kinase research.

• Radiopathomics Predicts Gastric Cancer Immunotherapy

  2026-08-21

  This 2025 Cancer Letters study combines baseline CT imaging, digital H&E pathology, and interpretable machine learning to predict response to immunotherapy-based combination treatment in gastric cancer. Across multicenter cohorts, its radiopathomics signature outperformed several conventional biomarkers and provided prognostic and immune-biological stratification, while still requiring prospective validation.

• AG-120 (Ivosidenib) Workflows for IDH1 AML

  2026-08-20

  This practical guide shows how to use AG-120 (Ivosidenib) to connect mutant IDH1 inhibition with 2-hydroxyglutarate reduction, proliferation control, and differentiation assays. It also translates new CD44-linked metabolic findings into experimental designs for pharmacodynamic testing, resistance studies, and combination screening.

• Doxycycline Hyclate: MMP Control in Translation

  2026-08-20

  Doxycycline hyclate is more than an antibiotic in translational research: it is a practical matrix metalloproteinases inhibitor for testing how MMP-2/MMP-9-driven blood-brain barrier injury contributes to neurotoxicity. Evidence from a sodium arsenite mouse model shows how this tool can connect molecular mechanism, experimental design, and translational strategy while preserving clear limits on interpretation.

• Poly (I:C) and Cardiomyocyte dsRNA Sensing

  2026-08-19

  Poly (I:C), a synthetic double-stranded RNA analog, is more than a generic interferon inducer: its experimental value depends on receptor compartment, cell state, and assay interpretation. This guide connects TLR3 stimulation with new insights into cardiomyocyte-autonomous MDA5 regulation and provides practical design guidance.

• Catalpol in Alzheimer’s Disease: Mechanisms and Evidence

  2026-08-19

  The 2022 review by Chen and colleagues synthesizes how catalpol, an iridoid glycoside from Rehmannia glutinosa, may influence Alzheimer’s disease through antioxidant, anti-inflammatory, antiapoptotic, and neuroprotective mechanisms. Its main practical value is the integration of heterogeneous cellular and animal evidence into a mechanistic framework, while also highlighting the limitations that separate preclinical findings from clinical translation.

• CHIR 99021 Trihydrochloride in Organoid Assays

  2026-08-18

  Explore how CHIR 99021 trihydrochloride functions as a selective GSK-3 inhibitor in stem-cell and intestinal organoid research. This evidence-led guide connects pathway mechanism with assay design, dose interpretation, controls, and translational limitations.

• Temafloxacin Pharmacokinetics: Findings and Relevance

  2026-08-18

  The reference study integrates oral and intravenous pharmacokinetic data to explain temafloxacin exposure, distribution, elimination, and dosing interval selection. Its findings support high oral bioavailability, an approximately 8-hour terminal half-life, and renal-function-based interval adjustment, while offering a useful analytical framework—but not direct dosing evidence—for evaluating chemically distinct agents such as Sulfamonomethoxine.

• GSDMC Drives PDAC Stemness and Immune Evasion

  2026-08-17

  A 2024 Advanced Science study identifies Gasdermin C (GSDMC) as a transcriptionally active regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion, independent of classical pyroptosis. The work links ADAM17-dependent cleavage and nuclear GSDMC localization to CXCL9-regulated immune remodeling and suggests that GSDMC targeting may improve responses to KRASG12D inhibition and PD-1 blockade.

453 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page